Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

866 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A comparative study of paediatric oral premedication: midazolam, ketamine and low dose combination of midazolam and ketamine.
Banerjee B, Bose A, Pahari S, Dan AK. Banerjee B, et al. Among authors: bose a. J Indian Med Assoc. 2011 Jun;109(6):386-8. J Indian Med Assoc. 2011. PMID: 22315765 Clinical Trial.
In a prospective randomised double-blind trial, 90 patients aged 1-7 years (ASA I) undergoing elective surgery less than 90 minutes duration were allocated into three separate groups to compare the safety and effectiveness of oral midazolam, ketamine, and low dose combinat …
In a prospective randomised double-blind trial, 90 patients aged 1-7 years (ASA I) undergoing elective surgery less than 90 minutes d …
Antibacterial properties in chlorophyll.
BOSE AB, SEN GUPTA PN. BOSE AB, et al. J Indian Med Assoc. 1946 Aug;15(11):361. J Indian Med Assoc. 1946. PMID: 20282747 No abstract available.
Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.
Bakish D, Bose A, Gommoll C, Chen C, Nunez R, Greenberg WM, Liebowitz M, Khan A. Bakish D, et al. Among authors: bose a. J Psychiatry Neurosci. 2014 Jan;39(1):40-9. doi: 10.1503/jpn.130040. J Psychiatry Neurosci. 2014. PMID: 24144196 Free PMC article. Clinical Trial.
BACKGROUND: Major depressive disorder (MDD) is a global health concern. This study examined the efficacy, safety and tolerability of an extended-release (ER) formulation of levomilnacipran, an antidepressant approved for the treatment of MDD in adults. ...For primary effic …
BACKGROUND: Major depressive disorder (MDD) is a global health concern. This study examined the efficacy, safety and tolerability of …
Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine.
Bose A, Tsai J, Li D. Bose A, et al. Clin Drug Investig. 2012 Jun 1;32(6):373-85. doi: 10.2165/11631890-000000000-00000. Clin Drug Investig. 2012. PMID: 22559255 Clinical Trial.
Up-titrating a well tolerated selective serotonin reuptake inhibitor (SSRI) versus switching to a serotonin norepinephrine reuptake inhibitor (SNRI) after initial SSRI non-response are possible treatment options. ...Treatment was single-blind escitalopram 10 mg/day …
Up-titrating a well tolerated selective serotonin reuptake inhibitor (SSRI) versus switching to a serotonin norepinephrine reu …
Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial.
Kornstein SG, Bose A, Li D, Saikali KG, Gandhi C. Kornstein SG, et al. Among authors: bose a. J Clin Psychiatry. 2006 Nov;67(11):1767-75. doi: 10.4088/jcp.v67n1115. J Clin Psychiatry. 2006. PMID: 17196058 Clinical Trial.
BACKGROUND: Major depressive disorder is a recurrent illness that often requires maintenance antidepressant treatment. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that has shown efficacy in both acute and continuation treatment of major depressiv …
BACKGROUND: Major depressive disorder is a recurrent illness that often requires maintenance antidepressant treatment. Escitalopram i …
A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder.
Bielski RJ, Bose A, Chang CC. Bielski RJ, et al. Among authors: bose a. Ann Clin Psychiatry. 2005 Apr-Jun;17(2):65-9. doi: 10.1080/10401230590932326. Ann Clin Psychiatry. 2005. PMID: 16075658 Clinical Trial.
BACKGROUND: This study compared the efficacy and tolerability of escitalopram, a newer SSRI, with paroxetine in the treatment of generalized anxiety disorder (GAD). ...CONCLUSIONS: These results support the use of escitalopram as a first-line treatment for GAD....
BACKGROUND: This study compared the efficacy and tolerability of escitalopram, a newer SSRI, with paroxetine in the treatment of gene …
Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting.
Rush AJ, Bose A. Rush AJ, et al. Among authors: bose a. Depress Anxiety. 2005;21(1):26-32. doi: 10.1002/da.20051. Depress Anxiety. 2005. PMID: 15786487 Clinical Trial.

At endpoint, response rates (defined as a score < or = 2 on the CGI-I or PGE) were 68% on the clinician-assessed CGI-I and 66% on the PGE. ...Escitalopram treatment was well tolerated and associated with robust response rates in a broadly representative populatio

At endpoint, response rates (defined as a score < or = 2 on the CGI-I or PGE) were 68% on the clinician-assessed CGI-I and 66% on

Escitalopram continuation treatment prevents relapse of depressive episodes.
Rapaport MH, Bose A, Zheng H. Rapaport MH, et al. Among authors: bose a. J Clin Psychiatry. 2004 Jan;65(1):44-9. doi: 10.4088/jcp.v65n0107. J Clin Psychiatry. 2004. PMID: 14744167 Clinical Trial.

Patients who met responder criteria (score of < or = 12 on the Montgomery-Asberg Depression Rating Scale [MADRS]) were randomly assigned in a 2:1 ratio to escitalopram (at the dose each patient was receiving at the end of the open-label phase) or placebo for 36 weeks of

Patients who met responder criteria (score of < or = 12 on the Montgomery-Asberg Depression Rating Scale [MADRS]) were randomly assigned

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
Burke WJ, Gergel I, Bose A. Burke WJ, et al. Among authors: bose a. J Clin Psychiatry. 2002 Apr;63(4):331-6. doi: 10.4088/jcp.v63n0410. J Clin Psychiatry. 2002. PMID: 12000207 Clinical Trial.
Clinical response was evaluated by the Montgomery-Asberg Depression Rating Scale (MADRS), the 24-item Hamilton Rating Scale for Depression (HAM-D), the Clinical Global Impressions (CGI) scales, the Hamilton Rating Scale for Anxiety (HAM-A), and patient-rated quality-of-lif …
Clinical response was evaluated by the Montgomery-Asberg Depression Rating Scale (MADRS), the 24-item Hamilton Rating Scale for Depression ( …
Escitalopram in the treatment of adolescent depression: a randomized, double-blind, placebo-controlled extension trial.
Findling RL, Robb A, Bose A. Findling RL, et al. Among authors: bose a. J Child Adolesc Psychopharmacol. 2013 Sep;23(7):468-80. doi: 10.1089/cap.2012.0023. J Child Adolesc Psychopharmacol. 2013. PMID: 24041408 Free PMC article. Clinical Trial.
METHODS: Adolescents (12-17 years) who completed an 8-week randomized, double-blind, flexible-dose, placebo-controlled, lead-in study of escitalopram 10-20 mg versus placebo could enroll in a 16-24-week, multisite extension trial; patients maintained the same lead-in rando …
METHODS: Adolescents (12-17 years) who completed an 8-week randomized, double-blind, flexible-dose, placebo-controlled, lead-in study of esc …
866 results
Jump to page
Feedback